Devices & Diagnostics

FDA approves Selenia 3-D mammography tool

A new innovative medical device from Hologic for performing mammograms was approved by the U.S. Food and Drug Administration. The Selenia FDA approval means physicians will have access to "unique and innovative 3-D technology that could significantly enhance existing diagnosis and treatment approaches," Center for Devices & Radiological Health chief Dr. Jeffrey Shuren stated.

Devices & Diagnostics

Hologic to distribute Angiotech breast biopsy device

A new private-label deal will see Hologic Inc. distributing a soft tissue biopsy instrument manufactured by Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) inked a three-year, private-label deal with Bedford, Mass.-based Hologic Inc. (NSDQ:HOLX). Under the terms of the agreement, Vancouver-based Angiotech will supply Hologic with its soft tissue biopsy device for breast biopsies. The […]

MedCity Influencers

Hologic’s 3D breast exam system close to FDA approval

Hologic Inc.’s (NASDAQ:HOLX) long wait to launch its 3D breast exam system is close to over. The company received an “approvable letter” from the Food & Drug Administration for its Selenia Dimensions 3-D digital mammography tomosynthesis system. The letter indicates that the final approval of the device maker’s pre-market approval application for the breast exam […]

Devices & Diagnostics

Hologic acquires Sentinelle Medical for $85 million

Hologic Inc. (NSDQ:HOLX) agreed to acquire Sentinelle Medical Inc. for $85 million plus contingencies. The deal calls for Bedford, Mass.-based Hologic to pay a “two-year contingent earn out,” according to a press release, for Toronto-based Sentinelle, which makes MRI breast coils, tables and visualization software. The earn-out involves cash payments equal to a multiple of […]

Devices & Diagnostics

C.R. Bard acquires SenoRx for $200 million

C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share. C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO). The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share. C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May […]